Xiao S - Search Results

1

Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.

Han X, Luo R, Wang L, Zhang L, Wang T, Zhao Y, Xiao S, Qiao N, Xu C, Ding L, Zhang Z, Shi Y. Han X, et al. Among authors: xiao s. Am J Cancer Res. 2020 Dec 1;10(12):4266-4286. eCollection 2020. Am J Cancer Res. 2020. PMID: 33414999 Free PMC article.

2

Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.

Yang Y, Zhou J, Zhou J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Guo Y, Zhou C, Ma K, Fang J, Feng W, Liu Y, Zheng Z, Li G, Wu N, Song W, Liu X, Zhao S, Ding L, Mao L, Selvaggi G, Yuan X, Fu Y, Wang T, Xiao S, Zhang L. Yang Y, et al. Among authors: xiao s. Lancet Respir Med. 2020 Jan;8(1):45-53. doi: 10.1016/S2213-2600(19)30252-8. Epub 2019 Oct 15. Lancet Respir Med. 2020. PMID: 31628085 Clinical Trial.

3

Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing.

Yang Y, Huang J, Wang T, Zhou J, Zheng J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y, Song Y, Hu Y, Yu Z, Gong Y, Chen Y, Ye F, Zhang S, Cao L, Fan Y, Wu G, Guo Y, Zhou C, Ma K, Fang J, Feng W, Liu Y, Zheng Z, Li G, Wang H, Cang S, Wu N, Song W, Liu X, Zhao S, Ding L, Mao L, Selvaggi G, Zhu L, Xiao S, Yuan X, Shen Z, Zhang L. Yang Y, et al. Among authors: xiao s. J Thorac Oncol. 2021 May;16(5):827-839. doi: 10.1016/j.jtho.2021.01.1615. Epub 2021 Feb 13. J Thorac Oncol. 2021. PMID: 33588113 Free article. Clinical Trial.

4

Integrated Multiomics Analyses Revealing Different Molecular Profiles Between Early- and Late-Stage Lung Adenocarcinoma.

Yue D, Liu W, Gao L, Zhang L, Wang T, Xiao S, Fu Y, Li N, Lin R, Hu Y, Ding L, Zhang Z, Zhang B, Wang C. Yue D, et al. Among authors: xiao s. Front Oncol. 2021 Oct 21;11:746943. doi: 10.3389/fonc.2021.746943. eCollection 2021. Front Oncol. 2021. PMID: 34745971 Free PMC article.

5

Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.

Feng Y, Sun W, Zhang J, Wang Y, Chen J, Liu X, Wang L, Li S, Lv C, Lu F, Zhang J, Hong Y, Xiao S, Wang T, Jiao R, Wang Z, Qi L, Li N, Yang Y, Lin D, Fang J. Feng Y, et al. Among authors: xiao s. Thorac Cancer. 2022 Feb;13(3):442-452. doi: 10.1111/1759-7714.14280. Epub 2021 Dec 15. Thorac Cancer. 2022. PMID: 34913597 Free PMC article.

6

PEAC: An Ultrasensitive and Cost-Effective MRD Detection System in Non-small Cell Lung Cancer Using Plasma Specimen.

Xu J, Pu Y, Lin R, Xiao S, Fu Y, Wang T. Xu J, et al. Among authors: xiao s. Front Med (Lausanne). 2022 Mar 3;9:822200. doi: 10.3389/fmed.2022.822200. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35308511 Free PMC article.

7

Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC).

Hui Z, Zhang J, Ren Y, Li X, Yan C, Yu W, Wang T, Xiao S, Chen Y, Zhang R, Wei F, You J, Ren X. Hui Z, et al. Among authors: xiao s. Cell Death Dis. 2022 Jul 13;13(7):607. doi: 10.1038/s41419-022-05057-4. Cell Death Dis. 2022. PMID: 35831283 Free PMC article.

8

Ensartinib in advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, two-staged, phase 1 trial.

Ma Y, Pan H, Liu Y, Zhang Y, Hong S, Huang J, Weng S, Yang Y, Fang W, Huang Y, Xiao S, Wang T, Ding L, Cui L, Zhang L, Zhao H. Ma Y, et al. Among authors: xiao s. J Thorac Dis. 2022 Dec;14(12):4751-4762. doi: 10.21037/jtd-22-1606. J Thorac Dis. 2022. PMID: 36647478 Free PMC article.

9

PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127⁺ and KLRG1⁺ CD8 T cells.

Hui Z, Ren Y, Zhang D, Chen Y, Yu W, Cao J, Liu L, Wang T, Xiao S, Zheng L, Pu Y, Wei F, You J, Ren X. Hui Z, et al. Among authors: xiao s. NPJ Precis Oncol. 2023 May 25;7(1):48. doi: 10.1038/s41698-023-00384-x. NPJ Precis Oncol. 2023. PMID: 37231145 Free PMC article.

10

Single-cell RNA-seq analyses inform necroptosis-associated myeloid lineages influence the immune landscape of pancreas cancer.

Dong W, Zhao H, Xiao S, Zheng L, Fan T, Wang L, Zhang H, Hu Y, Yang J, Wang T, Xiao W. Dong W, et al. Among authors: xiao s, xiao w. Front Immunol. 2023 Dec 12;14:1263633. doi: 10.3389/fimmu.2023.1263633. eCollection 2023. Front Immunol. 2023. PMID: 38149248 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,557 results

Search Page

Filters